Merck/Portola's betrixaban shows bleeding benefit in Phase IIb
16 March 2010
Asher Mullard
Merck/ Portola Pharmaceuticals' investigational Factor Xa inhibiting
anticoagulant betrixaban was associated with significantly less clinically
relevant bleeding than warfarin when given at 40mg/day to patients with
atrial fibrillation, show new results from a dose-finding study presented on...
Please Login to read the full article.
16 March 2010
Asher Mullard
Please Login to read the full article.
RELATED CONTENT
NEWS
- Pradaxa gets stroke prevention nod in the EU
- BMS/Pfizer's Eliquis better than Lovenox, but comparison with Pradaxa and Xarelto not clear, says NICE
- BMS/Pfizer set for European Eliquis launch after VTE prevention approval
- Portola ready to go it alone after Merck bows out of factor Xa partnership
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
